What Path Fertility does

Path Fertility is a private molecular diagnostics company, operating as a brand of Inherent Biosciences, Inc., headquartered in Salt Lake City, Utah, with Delaware incorporation. Founded in 2018 by CEO Andy Olson and CSO Dr. Kristin Brogaard (PhD, Northwestern), the company develops epigenetic sperm quality tests that use DNA methylation analysis to assess male fertility potential beyond what conventional semen analysis measures. Its core technology platform analyzes methylation patterns on sperm DNA as a biomarker of sperm function — measuring the sperm's ability to swim, find, bind to, penetrate, and fertilize an egg — rather than relying on 1950s-era microscopy-based semen analysis.

The company's flagship product is SpermQT, an at-home mail-in sperm quality test priced at $385 per kit, launched in 2022, with results delivered within approximately two weeks. In January 2026, Path Fertility expanded its portfolio with NOA Guide, an epigenetic diagnostic for non-obstructive azoospermia that uses native-read sequencing to detect sperm-derived cell-free DNA and guide surgical decision-making for TESE/micro-TESE. The SpermQT algorithm has been validated in a real-world, multi-site peer-reviewed study published in the Journal of Assisted Reproduction and Genetics covering 537 couples across 10 U.S. fertility clinics, demonstrating 22% pregnancy rates with normal SpermQT results versus 0% with abnormal results in IUI completions.

Path Fertility operates a hybrid go-to-market model, selling SpermQT directly to consumers through pathfertility.com and embedding it within three major U.S. fertility clinic networks for provider-ordered testing. The company is currently raising $5 million in funding to support commercialization and is pursuing clinical guideline inclusion to drive broader adoption across U.S. fertility clinics, with management projecting over $100 million in annual revenue by 2030.

Name

Path Fertility

Legal name

Inherent Biosciences, Inc.

Website

https://pathfertility.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Path Fertility is a private molecular diagnostics company that develops epigenetic sperm quality tests, including the SpermQT at-home mail-in kit, to predict male fertility potential and guide IUI versus IVF treatment decisions for couples experiencing infertility and their fertility specialists.

Ownership category

akta.pro rank

Product category

Male Fertility Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)

akta.pro secondary industries

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Genetic & Prenatal Testing Laboratories (HLAFAMAH)

Keywords

• Epigenetic sperm testing
• Male fertility diagnostics
• DNA methylation analysis
• Reproductive health testing
• Fertility treatment planning

Headquarters

HQ city

Salt Lake City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. SpermQT Test Sales: Path Fertility sells its SpermQT epigenetic sperm test directly to consumers via its website and through fertility clinic networks. The cash price is $385 per test. Results are delivered within approximately 10–14 days after sample collection.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Path Fertility develops and sells epigenetic sperm quality tests that analyze DNA methylation patterns on sperm DNA to predict male fertility potential and pregnancy outcomes. Its flagship SpermQT test is an at-home mail-in diagnostic that assesses whether sperm can functionally swim, find, bind to, penetrate, and fertilize an egg — going beyond standard semen analysis which only measures count and motility — and is used by couples and fertility clinics to guide IUI vs. IVF/ICSI treatment decisions.

Product overview

Path Fertility offers a portfolio of epigenetic-based male fertility diagnostic products. The flagship product SpermQT is an at-home mail-in sperm quality test launched in 2022 that analyzes DNA methylation patterns to predict fertility outcomes where standard semen analysis fails. NOA Guide is an additional epigenetic diagnostic for non-obstructive azoospermia, launched January 2026, which detects sperm-derived cell-free DNA to guide surgical sperm extraction decisions. Both products operate on the same epigenetic technology platform but address different stages of male infertility diagnosis and treatment planning.

Differentiator

Problem solved

Functional benefit

Brands

• SpermQT: Epigenetic sperm quality test that predicts pregnancy outcomes by measuring sperm function, not just sperm count. Cash price of $385.
• NOA Guide

Products and services

• SpermQT An at-home mail-in epigenetic sperm quality test that analyzes DNA methylation patterns on sperm DNA to assess functional sperm capability (swim, find, bind, penetrate, and fertilize the egg) and predict pregnancy outcomes for IUI vs. IVF/ICSI decisions. Sold directly to consumers via pathfertility.com at a $385 cash price and through fertility clinic networks; results delivered within approximately 2 weeks of sample collection.
• NOA Guide An epigenetic diagnostic test for non-obstructive azoospermia (NOA) that uses native-read sequencing technology to detect sperm-derived cell-free DNA in seminal samples. Designed for reproductive urologists and fertility specialists to identify which NOA patients are most likely to benefit from TESE/micro-TESE surgical sperm extraction.

Quantifiable outcome

• Among 202 couples who completed IUI, 22% with normal SpermQT results achieved pregnancy compared to 0% with abnormal results, while IVF-ICSI outcomes remained unaffected by test results.
• +3 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

One partnership is on record.

• Renew BiotechnologiescoreTechnology or Integration · 29 January 2026Renew Biotechnologies serves as the clinical testing provider for Path Fertility's NOA Guide, a new epigenetic diagnostic test for male infertility. Renew leverages its native-read sequencing technology to detect sperm-derived cell-free DNA in seminal samples, aiming to improve surgical decision-making for men with non-obstructive azoospermia.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• CooperSurgical: CooperSurgical is a major incumbent in the fertility/ART market, providing a broad portfolio of IVF consumables, lab equipment, and diagnostics. A potential strategic acquirer or competitor to Path Fertility's clinic-embedded diagnostic channel.
• Ro (Roman): Ro operates a men's health platform that includes mail-in fertility testing and treatment offerings. While broader in scope than Path Fertility, it competes in the same DTC male fertility diagnostic category with significantly more capital and brand reach.
• Myriad Genetics: Myriad Genetics provides genetic and molecular diagnostic tests across multiple specialties including reproductive health. Overlaps with Path Fertility in molecular diagnostics methodology and clinical lab operations, though at much greater scale.
• Natera: Natera is a major reproductive genetics company offering NIPT, PGT, and other genetic testing in the fertility/pregnancy pathway. Comparable to Path Fertility in applying molecular/genetic diagnostics to reproductive medicine, though at a much larger scale.
• Hamilton Thorne: Hamilton Thorne manufactures computer-assisted sperm analysis (CASA) systems and ART lab equipment used in fertility clinics. Overlaps with Path Fertility in serving fertility clinics with sperm-related diagnostic/analytical tools.

Direct peers

• Fellow: Fellow offers at-home mail-in semen analysis and sperm DNA fragmentation testing for individuals and couples. Comparable to Path Fertility in DTC mail-in male fertility testing, though without the epigenetic differentiation.
• Mojo Fertility: Mojo provides mail-in sperm analysis testing with optional DNA fragmentation, sold DTC and through clinics. Directly comparable to Path Fertility's SpermQT in distribution model, target customer, and male fertility diagnostic positioning.
• Legacy: Legacy offers at-home mail-in male fertility testing with semen analysis and sperm DNA fragmentation, sold DTC. Direct competitor to SpermQT in the mail-in male fertility testing category, targeting similar couples and clinics.

Emerging players

• Phosphorus: Phosphorus is a genetic testing lab offering reproductive and carrier screening panels. Comparable in molecular diagnostics lab operations and reproductive health testing focus, though more focused on female-side and carrier genetics.
• Sema4 (now part of GeneDx): Sema4/GeneDx provides genetic and genomic testing including reproductive health offerings. Comparable as a molecular diagnostics lab platform, though with broader scope beyond male fertility.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/PathFertility
• LinkedInlinkedin.com/company/pathfertility

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Path Fertility